Functional role of p68 tyrosine phosphorylation in cancer metastasis
p68 酪氨酸磷酸化在癌症转移中的功能作用
基本信息
- 批准号:7487547
- 负责人:
- 金额:$ 21.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAntibodiesBiological AssayBoxingCancer PatientCancer cell lineCancerousCell NucleusCell PolarityCellsCessation of lifeChimeric ProteinsColon CarcinomaComplexConditionCytoplasmDeacetylationDevelopmentDiagnosisDisseminated Malignant NeoplasmDsRedEpithelialEpithelial CellsEventGenesGenetic TranscriptionGoalsHDAC1 geneHT29 CellsHumanImmunoblottingImplantLeadLeftLocalizedMalignant NeoplasmsMediatingMesenchymalModelingMolecularMonitorMorphologyNeoplasm MetastasisNuRD complexNuclearNuclear TranslocationNude MiceOrganPathway interactionsPhosphorylationPlatelet-Derived Growth FactorPlayProcessPropertyProteinsRNA HelicaseResearch PersonnelResearch ProposalsRoleSnailsStaining methodStainsTestingTissue SampleTissuesTyrosineTyrosine PhosphorylationUp-RegulationXenograft procedurebeta catenincancer celldesignenhanced green fluorescent proteinheterokaryonmouse modelmutantneoplastic cellnoveloutcome forecastprogramspromoterprotein p68protein protein interactionresearch studysnail proteintumor progression
项目摘要
DESCRIPTION (provided by applicant): We have: observed that p68 RNA helicase acquired substantially higher level of phosphorylation(s) at tyrosine residues in both metastatic cancer cell lines and tissue samples compared to that in non-metastatic cancer cell lines and tissue samples. P68 is not phosphorylated in non-cancerous tissues. We also found that phosphorylation of p68 at tyrosine 593 is required for epithelial-mesenchymal-transition (EMT), a critical event for cancer metastasis. The phosphorylated p68 promotes EMT by facilitating beta-catenin nuclear translocation and activating transcription of Snail gene. Our hypothesis is that the phosphorylated p68 is a new and important regulatory factor that plays important role(s) in promoting EMT and tumor progression/metastasis. The goals of this research proposal are two fold: (1) to gain a comprehensive understanding of the molecular mechanism by which the phospho-p68 promotes EMT, and (2) to extensively test the role of the phospho-p68 in promoting cancer metastasis. In specific aim 1, we propose experiments to test the role of the p68 phosphorylation in promoting cancer metastasis both in xenograft mice model and in tissue samples from cancer patients. In specific aim 2, we design experiments to elucidate the mechanism by which the phospho-p68 activates Snail gene transcription. We will test whether the phospho- p68 use its protein-dependent ATPase activity to 'displace' HDAC1 from remodeling and deacetylation complex (NuRD) at Snail promoter. Most cancer-related deaths are the consequence of the cancer metastasis. Although an outline picture about the process of cancer metastasis is emerge, the detailed mechanism is still far beyond fully understanding, especially the cellular factors that contribute to each steps of cancer metastasis. In specific aim 3, we propose experiments to test whether the phospho-p68 actively 'transports' cytoplasmic beta-catenin to the nucleus. Our study will uncover a new molecular factor that is involved in cancer metastasis. Understanding the functional role of phospho-p68 will ultimately be applied to develop new strategies to the diagnosis/prognosis and treatment for cancer metastasis.
描述(由申请人提供):我们有:观察到,在转移性癌细胞系和组织样品中,P68 RNA解旋酶在酪氨酸残基上获得了较高水平的磷酸化水平,而不是在非中性癌细胞系和组织样品中。 p68在非癌组织中未磷酸化。我们还发现,上皮 - 间质转换(EMT)需要p68在酪氨酸593处的磷酸化,这是癌症转移的关键事件。磷酸化的p68通过促进β-catenin核易位并激活蜗牛基因的转录来促进EMT。我们的假设是,磷酸化的p68是一种新的重要调节因素,在促进EMT和肿瘤进展/转移中起重要作用。该研究建议的目标是两个方面:(1)对磷酸-P68促进EMT的分子机制的全面了解,以及(2)广泛测试磷酸-P68在促进癌症转移中的作用。在特定目标1中,我们提出了实验,以测试p68磷酸化在异种移植小鼠模型中促进癌症转移和癌症患者的组织样本中的作用。在特定目标2中,我们设计了实验,以阐明磷酸-P68激活蜗牛基因转录的机制。我们将测试磷酸p68是否使用其蛋白质依赖性ATPase活性来从蜗牛启动子上的重塑和脱乙酰化复合物(NURD)中“位移” HDAC1。大多数与癌症有关的死亡是癌症转移的结果。尽管出现了有关癌症转移过程的轮廓图,但详细的机制仍然远远超出了完全理解的范围,尤其是导致癌症转移步骤的每个步骤的细胞因素。在特定的目标3中,我们提出了实验,以测试磷酸-P68是否会主动将胞质β-catenin“转运”到核中。我们的研究将发现与癌症转移有关的新分子因子。了解磷酸-P68的功能作用最终将用于制定新的策略,以诊断/预后和治疗癌症转移。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhi-Ren Liu其他文献
Zhi-Ren Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhi-Ren Liu', 18)}}的其他基金
A treatment drug for triple negative breast cancer
一种治疗三阴性乳腺癌的药物
- 批准号:
10643890 - 财政年份:2022
- 资助金额:
$ 21.96万 - 项目类别:
A treatment drug for triple negative breast cancer
一种治疗三阴性乳腺癌的药物
- 批准号:
10483825 - 财政年份:2022
- 资助金额:
$ 21.96万 - 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
- 批准号:
10551992 - 财政年份:2017
- 资助金额:
$ 21.96万 - 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
- 批准号:
9765276 - 财政年份:2017
- 资助金额:
$ 21.96万 - 项目类别:
Development of a protein drug for pancreatic cancer treatment
开发治疗胰腺癌的蛋白质药物
- 批准号:
10250688 - 财政年份:2017
- 资助金额:
$ 21.96万 - 项目类别:
PKM2 coordinates glycolysis and glutaminolysis in cancer cells
PKM2 协调癌细胞中的糖酵解和谷氨酰胺分解
- 批准号:
8788258 - 财政年份:2014
- 资助金额:
$ 21.96万 - 项目类别:
Development of anti-angiogenesis therapy targeting integrin
针对整合素的抗血管生成疗法的开发
- 批准号:
9023506 - 财政年份:2014
- 资助金额:
$ 21.96万 - 项目类别:
Development of anti-angiogenesis therapy targeting integrin
针对整合素的抗血管生成疗法的开发
- 批准号:
8631535 - 财政年份:2014
- 资助金额:
$ 21.96万 - 项目类别:
PKM2 coordinates glycolysis and glutaminolysis in cancer cells
PKM2 协调癌细胞中的糖酵解和谷氨酰胺分解
- 批准号:
8621210 - 财政年份:2014
- 资助金额:
$ 21.96万 - 项目类别:
P68 and Ca-calmodulin interaction in cell migration
P68 和 Ca-钙调蛋白在细胞迁移中的相互作用
- 批准号:
8693188 - 财政年份:2007
- 资助金额:
$ 21.96万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The Center for Synovial Sarcoma Biology and Therapeutics
滑膜肉瘤生物学和治疗中心
- 批准号:
10797558 - 财政年份:2023
- 资助金额:
$ 21.96万 - 项目类别:
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
开发 RUVBL1/2 抑制剂作为 NSCLC 的放射增敏剂和免疫刺激剂
- 批准号:
10733863 - 财政年份:2023
- 资助金额:
$ 21.96万 - 项目类别:
Mechanisms of sperm chromatin remodeling in vivo and in vitro
精子染色质体内外重塑机制
- 批准号:
10753662 - 财政年份:2023
- 资助金额:
$ 21.96万 - 项目类别:
Peroxisomal fatty acid metabolism in genetic and age-related disorders
遗传和年龄相关疾病中的过氧化物酶体脂肪酸代谢
- 批准号:
10559614 - 财政年份:2022
- 资助金额:
$ 21.96万 - 项目类别:
Defining the role of the BCL7 subunit of mammalian SWI/SNF chromatin remodeling complexes in human cancer
确定哺乳动物 SWI/SNF 染色质重塑复合物的 BCL7 亚基在人类癌症中的作用
- 批准号:
10450322 - 财政年份:2022
- 资助金额:
$ 21.96万 - 项目类别: